These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 14692881)

  • 1. The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease.
    Heiss WD; Hilker R
    Eur J Neurol; 2004 Jan; 11(1):5-12. PubMed ID: 14692881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.
    Thobois S; Guillouet S; Broussolle E
    Neurophysiol Clin; 2001 Oct; 31(5):321-40. PubMed ID: 11817273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [PET study using 6-[18F]-fluorodopa in Parkinson's disease].
    Nagasawa H; Tanji H; Itoh M; Itoyama Y
    Nihon Rinsho; 1997 Jan; 55(1):213-7. PubMed ID: 9014452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary parkinsonism due to focal substantia nigra lesions: a PET study with [18F]FDG and [18F]fluorodopa.
    Boecker H; Weindl A; Leenders K; Antonini A; Kuwert T; Kruggel F; Grafin von Einsiedel H; Conrad B
    Acta Neurol Scand; 1996 Jun; 93(6):387-92. PubMed ID: 8836298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging.
    Ghaemi M; Hilker R; Rudolf J; Sobesky J; Heiss WD
    J Neurol Neurosurg Psychiatry; 2002 Nov; 73(5):517-23. PubMed ID: 12397143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
    Pirker W
    Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies.
    Eidelberg D; Moeller JR; Dhawan V; Sidtis JJ; Ginos JZ; Strother SC; Cedarbaum J; Greene P; Fahn S; Rottenberg DA
    Mov Disord; 1990; 5(3):203-13. PubMed ID: 2117706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is altropane SPECT more sensitive to fluoroDOPA PET for detecting early Parkinson's disease?
    Fernandez HH; Friedman JH; Fischman AJ; Noto RB; Lannon MC
    Med Sci Monit; 2001; 7(6):1339-43. PubMed ID: 11687754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [18F]FDOPA PET as an endophenotype for Parkinson's Disease linkage studies.
    Racette BA; Good L; Antenor JA; McGee-Minnich L; Moerlein SM; Videen TO; Perlmutter JS
    Am J Med Genet B Neuropsychiatr Genet; 2006 Apr; 141B(3):245-9. PubMed ID: 16528749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms.
    Kumakura Y; Gjedde A; Danielsen EH; Christensen S; Cumming P
    J Cereb Blood Flow Metab; 2006 Mar; 26(3):358-70. PubMed ID: 16079784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative assessment of 6-[
    Becker G; Bahri MA; Michel A; Hustadt F; Garraux G; Luxen A; Lemaire C; Plenevaux A
    J Neurochem; 2017 May; 141(4):626-635. PubMed ID: 28294334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease.
    Brooks DJ
    J Neurol; 2000 Apr; 247 Suppl 2():II11-8. PubMed ID: 10991656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status and future challenges of brain imaging with (18)F-DOPA PET for movement disorders.
    Calabria FF; Calabria E; Gangemi V; Cascini GL
    Hell J Nucl Med; 2016; 19(1):33-41. PubMed ID: 26929938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity.
    Hilker R; Schweitzer K; Coburger S; Ghaemi M; Weisenbach S; Jacobs AH; Rudolf J; Herholz K; Heiss WD
    Arch Neurol; 2005 Mar; 62(3):378-82. PubMed ID: 15767502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
    Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
    Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.
    Ishikawa T; Dhawan V; Chaly T; Robeson W; Belakhlef A; Mandel F; Dahl R; Margouleff C; Eidelberg D
    J Cereb Blood Flow Metab; 1996 Sep; 16(5):854-63. PubMed ID: 8784230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 99mTc-TRODAT-1 SPECT in healthy and 6-OHDA lesioned parkinsonian monkeys: comparison with 18F-FDOPA PET.
    Huang WS; Ma KH; Chou YH; Chen CY; Liu RS; Liu JC
    Nucl Med Commun; 2003 Jan; 24(1):77-83. PubMed ID: 12501023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA.
    Cropley VL; Fujita M; Bara-Jimenez W; Brown AK; Zhang XY; Sangare J; Herscovitch P; Pike VW; Hallett M; Nathan PJ; Innis RB
    Psychiatry Res; 2008 Jul; 163(2):171-82. PubMed ID: 18504119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.